Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Guanxinning Tablet Therapy in Acute Coronary Syndrome
ChiCTR2100054620Phase 4Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Jun 2021
- Countries
- 1
01
Overview
Phase 4 trial of Guanxinning in acute coronary syndrome (ACS), myocardial infarction (MI) and unstable angina (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoints: Antiplatelet aggregation rate, Inflammation-related factors and 6 more. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
Guanxinning
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)unstable angina
Beyond the preview
Go deeper on ChiCTR2100054620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054620.